Waqas Ahmad

Dr. Waqas Ahmad

Stritch School of Medicine, Loyola University Chicago, Chicago, Illinois, USA
+2
orcid
University of Cincinnati

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2025 in The Lancet
Verified
Journal Article
Open access
Waqas AhmadWaqas Ahmad
Waqas Ahmad
For more than three decades, the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) has provided a framework to quantify health loss due to diseases, injuries, and associated risk factors. This paper presents GBD 2023 findings on disease and injury burden and risk-attributable health loss, offering a global audit of the state of world health to inform public health priorities. This work captures the evolving landscape of health metrics across age groups, sexes, and locations, while reflecting on the remaining post-COVID-19 challenges to achieving our collective global health ambitions. The GBD 2023 combined analysis estimated years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs) for 375 diseases and injuries, and risk-attributable burden associated with 88 modifiable risk factors. Of the more than 310 000 total data sources used for all GBD 2023 (about 30% of which were new to this estimation round), more than 120 000 sources were used for estimation of disease and injury burden and 59 000 for risk factor estimation, and included vital registration systems, surveys, disease registries, and published scientific literature. Data were analysed using previously established modelling approaches, such as disease modelling meta-regression version 2.1 (DisMod-MR 2.1) and comparative risk assessment methods. Diseases and injuries were categorised into four levels on the basis of the established GBD cause hierarchy, as were risk factors using the GBD risk hierarchy. Estimates stratified by age, sex, location, and year from 1990 to 2023 were focused on disease-specific time trends over the 2010-23 period and presented as counts (to three significant figures) and age-standardised rates per 100 000 person-years (to one decimal place). For each measure, 95% uncertainty intervals [UIs] were calculated with the 2·5th and 97·5th percentile ordered values from a 250-draw distribution. Total numbers of global DALYs grew 6·1% (95% UI 4·0-8·1), from 2·64 billion (2·46-2·86) in 2010 to 2·80 billion (2·57-3·08) in 2023, but age-standardised DALY rates, which account for population growth and ageing, decreased by 12·6% (11·0-14·1), revealing large long-term health improvements. Non-communicable diseases (NCDs) contributed 1·45 billion (1·31-1·61) global DALYs in 2010, increasing to 1·80 billion (1·63-2·03) in 2023, alongside a concurrent 4·1% (1·9-6·3) reduction in age-standardised rates. Based on DALY counts, the leading level 3 NCDs in 2023 were ischaemic heart disease (193 million [176-209] DALYs), stroke (157 million [141-172]), and diabetes (90·2 million [75·2-107]), with the largest increases in age-standardised rates since 2010 occurring for anxiety disorders (62·8% [34·0-107·5]), depressive disorders (26·3% [11·6-42·9]), and diabetes (14·9% [7·5-25·6]). Remarkable health gains were made for communicable, maternal, neonatal, and nutritional (CMNN) diseases, with DALYs falling from 874 million (837-917) in 2010 to 681 million (642-736) in 2023, and a 25·8% (22·6-28·7) reduction in age-standardised DALY rates. During the COVID-19 pandemic, DALYs due to CMNN diseases rose but returned to pre-pandemic levels by 2023. From 2010 to 2023, decreases in age-standardised rates for CMNN diseases were led by rate decreases of 49·1% (32·7-61·0) for diarrhoeal diseases, 42·9% (38·0-48·0) for HIV/AIDS, and 42·2% (23·6-56·6) for tuberculosis. Neonatal disorders and lower respiratory infections remained the leading level 3 CMNN causes globally in 2023, although both showed notable rate decreases from 2010, declining by 16·5% (10·6-22·0) and 24·8% (7·4-36·7), respectively. Injury-related age-standardised DALY rates decreased by 15·6% (10·7-19·8) over the same period. Differences in burden due to NCDs, CMNN diseases, and injuries persisted across age, sex, time, and location. Based on our risk analysis, nearly 50% (1·27 billion [1·18-1·38]) of the roughly 2·80 billion total global DALYs in 2023 were attributable to the 88 risk factors analysed in GBD. Globally, the five level 3 risk factors contributing the highest proportion of risk-attributable DALYs were high systolic blood pressure (SBP), particulate matter pollution, high fasting plasma glucose (FPG), smoking, and low birthweight and short gestation-with high SBP accounting for 8·4% (6·9-10·0) of total DALYs. Of the three overarching level 1 GBD risk factor categories-behavioural, metabolic, and environmental and occupational-risk-attributable DALYs rose between 2010 and 2023 only for metabolic risks, increasing by 30·7% (24·8-37·3); however, age-standardised DALY rates attributable to metabolic risks decreased by 6·7% (2·0-11·0) over the same period. For all but three of the 25 leading level 3 risk factors, age-standardised rates dropped between 2010 and 2023-eg, declining by 54·4% (38·7-65·3) for unsafe sanitation, 50·5% (33·3-63·1) for unsafe water source, and 45·2% (25·6-72·0) for no access to handwashing facility, and by 44·9% (37·3-53·5) for child growth failure. The three leading level 3 risk factors for which age-standardised attributable DALY rates rose were high BMI (10·5% [0·1 to 20·9]), drug use (8·4% [2·6 to 15·3]), and high FPG (6·2% [-2·7 to 15·6]; non-significant). Our findings underscore the complex and dynamic nature of global health challenges. Since 2010, there have been large decreases in burden due to CMNN diseases and many environmental and behavioural risk factors, juxtaposed with sizeable increases in DALYs attributable to metabolic...

15 May 2020 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
SASyeda Roohina Ali
Syeda Roohina Ali
Waqas AhmadWaqas Ahmad
Waqas Ahmad
NNNadia Naeem
Nadia Naeem
ASAsmat Salim
Asmat Salim
Irfan KhanIrfan Khan
Irfan Khan

1 July 2025 in Annals of Palliative Medicine
Verified
Journal Article
Open access
PDF file
BWBoyu Wang
Boyu Wang
XHXingyu He
Xingyu He
SDSuchandrima Dutta
Suchandrima Dutta
SCSophie Chen
Sophie Chen
JLJialiang Liang
Jialiang Liang
YWYigang Wang
Yigang Wang
Breast cancer, a heterogeneous malignancy with a significant global burden, necessitates evolving therapeutic strategies. With nearly two million new cases diagnosed annually, metastatic dissemination remains a critical clinical challenge despite advancements in surgery, radiotherapy, and cytotoxic chemotherapy. The emergence of targeted therapies, including monoclonal antibodies, small-molecule inhibitors, and antibody-drug conjugates (ADCs), has revolutionized breast cancer management by selectively modulating oncogenic signaling pathways to inhibit tumor proliferation and spread. This approach offers a more focused treatment strategy with the potential for reduced systemic toxicities. Targeted therapies have demonstrated significant clinical efficacy across breast cancer subtypes. For instance, agents such as trastuzumab, pertuzumab, and trastuzumab emtansine (T-DM1) improved survival in human epidermal growth factor receptor 2 (HER2)-positive disease. Similarly, cyclin dependent kinase 4/6 (CDK4/6) and poly (ADP-ribose) polymerase (PARP) inhibitors have yielded substantial benefits in hormone receptor-positive and breast cancer gene (BRCA)-mutated breast cancers, respectively, by modulating endocrine resistance and DNA repair pathways. Furthermore, phosphoinositide 3-kinase (PI3K) inhibitors for PIK3CA-mutant tumors and immune checkpoint inhibitors for triple-negative breast cancer (TNBC) have expanded the available therapeutic measures. However, despite these advancements, challenges such as acquired resistance, often driven by pathway reactivation or gene mutations, continue to limit optimal patient outcomes. Additionally, treatment-related toxicities demand rigorous management, therefore ongoing identification of robust predictive biomarkers to refine patient selection and treatment strategies remains a critical focus of research. This mini-review provides a comprehensive overview of current targeted therapies in breast cancer, detailing their mechanisms of action, clinical efficacy, and associated toxicities. It addresses relevant challenges such as resistance pathways, financial toxicity, and gaps in biomarker research, while emphasizing the importance of patient-centered decision-making and multidisciplinary care. Future directions include the development of next-generation sequencing, refined drug designs, and the integration of immunotherapies to further improve patient outcomes and quality of life, ultimately striving towards personalized cancer care.

12 November 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
Krishan Gopal JainKrishan Gopal Jain
Krishan Gopal Jain
NXNan Miles Xi
Nan Miles Xi
RZRunzhen Zhao
Runzhen Zhao
Waqas AhmadWaqas Ahmad
Waqas Ahmad
GAGibran Ali
Gibran Ali
Hong-Long JiHong-Long Ji
Hong-Long Ji
Lung diseases rank third in terms of mortality and represent a significant economic burden globally. Scientists have been conducting research to better understand respiratory diseases and find treatments for them. An ideal in vitro model must mimic the in vivo organ structure, physiology, and pathology. Organoids are self-organizing, three-dimensional (3D) structures originating from adult stem cells, embryonic lung bud progenitors, embryonic stem cells (ESCs), and induced pluripotent stem cells (iPSCs). These 3D organoid cultures may provide a platform for exploring tissue development, the regulatory mechanisms related to the repair of lung epithelia, pathophysiological and immunomodulatory responses to different respiratory conditions, and screening compounds for new drugs. To create 3D lung organoids in vitro, both co-culture and feeder-free methods have been used. However, there exists substantial heterogeneity in the organoid culture methods, including the sources of AT2 cells, media composition, and feeder cell origins. This article highlights the currently available methods for growing AT2 organoids and prospective improvements to improve the available culture techniques/conditions. Further, we discuss various applications, particularly those aimed at modeling human distal lung diseases and cell therapy.

26 August 2022 in World Journal of Stem Cells
Verified
Journal Article
Open access
RQRida e Maria Qazi
Rida e Maria Qazi
Irfan KhanIrfan Khan
Irfan Khan
KHKanwal Haneef
Kanwal Haneef
TMTuba Shakil Malick
Tuba Shakil Malick
NNNadia Naeem
Nadia Naeem
SMSadia Mohsin
Sadia Mohsin
Cardiovascular diseases are the major cause of mortality worldwide. Regeneration of the damaged myocardium remains a challenge due to mechanical constraints and limited healing ability of the adult heart tissue. Cardiac tissue engineering using biomaterial scaffolds combined with stem cells and bioactive molecules could be a highly promising approach for cardiac repair. Use of biomaterials can provide suitable microenvironment to the cells and can solve cell engraftment problems associated with cell transplantation alone. Mesenchymal stem cells (MSCs) are potential candidates in cardiac tissue engineering because of their multilineage differentiation potential and ease of isolation. Use of DNA methyl transferase inhibitor, such as zebularine, in combination with three-dimensional (3D) scaffold can promote efficient MSC differentiation into cardiac lineage, as epigenetic modifications play a fundamental role in determining cell fate and lineage specific gene expression. To investigate the role of collagen scaffold and zebularine in the differentiation of rat bone marrow (BM)-MSCs and their subsequent in vivo effects. MSCs were isolated from rat BM and characterized morphologically, immunophenotypically and by multilineage differentiation potential. MSCs were seeded in collagen scaffold and treated with 3 μmol/L zebularine in three different ways. Cytotoxicity analysis was done and cardiac differentiation was analyzed at the gene and protein levels. Treated and untreated MSC-seeded scaffolds were transplanted in the rat myocardial infarction (MI) model and cardiac function was assessed by echocardiography. Cell tracking was performed by DiI dye labeling, while regeneration and neovascularization were evaluated by histological and immunohistochemical analysis, res pectively. MSCs were successfully isolated and seeded in collagen scaffold. Cytotoxicity analysis revealed that zebularine was not cytotoxic in any of the treatment groups. Cardiac differentiation analysis showed more pronounced results in the type 3 treatment group which was subsequently chosen for the transplantation in the in vivo MI model. Significant improvement in cardiac function was observed in the zebularine treated MSC-seeded scaffold group as compared to the MI control. Histological analysis also showed reduction in fibrotic scar, improvement in left ventricular wall thickness and preservation of ventricular remodeling in the zebularine treated MSC-seeded scaffold group. Immunohistochemical analysis revealed significant expression of cardiac proteins in DiI labeled transplanted cells and a significant increase in the number of blood vessels in the zebularine treated MSC-seeded collagen scaffold transplanted group. Combination of 3D collagen scaffold and zebularine treatment enhances cardiac differentiation potential of MSCs, improves cell engraftment at the infarcted region, reduces infarct size and improves cardiac function.

18 December 2024 in Cells
Verified
Journal Article
Open access
PDF file
Xingyu HeXingyu He
Xingyu He
AGAngela Good
Angela Good
WKWael Kalou
Wael Kalou
Waqas AhmadWaqas Ahmad
Waqas Ahmad
SDSUCHANDRIMA DUTTA
SUCHANDRIMA DUTTA
Yigang WangYigang Wang
Yigang Wang
Cardiovascular diseases resulting from myocardial infarction (MI) remain a leading cause of death worldwide, imposing a substantial burden on global health systems. Current MI treatments, primarily pharmacological and surgical, do not regenerate lost myocardium, leaving patients at high risk for heart failure. Engineered heart tissue (EHT) offers a promising solution for MI and related cardiac conditions by replenishing myocardial loss. However, challenges like immune rejection, inadequate vascularization, limited mechanical strength, and incomplete tissue maturation hinder clinical application. The discovery of human-induced pluripotent stem cells (hiPSCs) has transformed the EHT field, enabling new bioengineering innovations. This review explores recent advancements and future directions in hiPSC-derived EHTs, focusing on innovative materials and fabrication methods like bioprinting and decellularization, and assessing their therapeutic potential through preclinical and clinical studies. Achieving functional integration of EHTs in the heart remains challenging due to the need for synchronized contraction, sufficient vascularization, and mechanical compatibility. Solutions such as genome editing, personalized medicine, and AI technologies offer promising strategies to address these translational barriers. Beyond MI, EHTs also show potential in treating ischemic cardiomyopathy, heart valve engineering, and drug screening, underscoring their promise in cardiovascular regenerative medicine.